T2 Biosystems rises on contract for its sepsis-detecting diagnostics system

T2 Biosystems

30/05/2023 16:17

** Shares of in-vitro diagnostics co T2 Biosystems Inc
 TTOO.O  more than double to $0.22
    ** Stock set for its biggest one-day pct. gain ever
    ** Co says its distribution partner, Biomedica Poland,
secured a multi-year contract for its T2Dx instruments and
sepsis test panels that are expected to be deployed in selected
hospitals across Poland
    ** Co adds that it's the second-largest sale of
sepsis-driven T2Dx instruments in co's history
     ** The initial order includes seven T2Dx instruments,
valued at more than $450,000, with the potential for nine
additional instruments to be sold and deployed into an increased
number of hospitals in Poland during H2 2023 - TTOO
    ** T2Dx Instrument and sepsis test panels provides rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes
    ** Stock down ~86% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))